Press Releases by "Eisai Co., Ltd."

• Eisai and Sanko Junyaku to Launch Cobas h 232 Series, a Point-of-Care Testing System for Use in the Early Diagnosis of Cardiovascular Emergencies
  [ Pharmaceuticals | 2011-03-09]
• U.S. FDA APPROVES ANTI-EPILEPTIC AGENT BANZEL® (RUFINAMIDE) ORAL SUSPENSION, 40MG/ML Indicated for Adjunctive Treatment of Seizures Associated With Lennox-Gastaut Syndrome in Children 4 Years and Older and Adult
  [ Pharmaceuticals | 2011-03-04]
• THE LANCET PUBLISHES RESULTS FROM PIVOTAL STUDY OF EISAI’S HALAVEN® IN PATIENTS WITH LATE-STAGE METASTATIC BREAST CANCERPhase III Study Demonstrated that HALAVEN® Met its Primary Endpoint of Overall Survival
  [ Pharmaceuticals | 2011-03-03]
• EISAI TO DELAY NHI DRUG PRICE REGISTRATION AND LAUNCH OF NERBLOC®, A BOTULINUM TOXIN TYPE B NEUROMUSCULAR-BLOCKING AGENT
  [ Pharmaceuticals | 2011-02-28]
• EISAI'S ORAL ANTICOAGULANT WARFARIN TABLETS APPROVED FOR PEDIATRIC USE IN JAPAN
  [ Pharmaceuticals | 2011-02-23]
• INTELLECTUAL PROPERTY HIGH COURT OF JAPAN RULES TO MAINTAIN ARICEPT® PATENT TERM EXTENSION IN RELATION TO SEVERE ALZHEIMER'S DEMENTIA
  [ Pharmaceuticals | 2011-02-23]
• Eisai, Sanko Junyaku Commence Co-promotion of DT-Navi, a New Touch-Screen System to Help Physicians with ADAS-Jcog. Testing and Assessment of Cognitive Function Change
  [ Pharmaceuticals | 2011-02-22]
• EISAI TO EXPAND SALES OF CHOCOLA BB SERIES INTO ASIA -CHOCOLA BB® DRINK BIT SCHEDULED FOR LAUNCH IN HONG KONG-
  [ Pharmaceuticals | 2011-02-21]
• EISAI CONCLUDES JAPAN LICENSE AGREEMENT FOR NEW ARICEPT® TRANSDERMAL FORMULATION
  [ Pharmaceuticals | 2011-02-14]
• SINGAPORE HSA APPROVES EISAI’S HALAVEN® (ERIBULIN MESYLATE) INJECTION FOR TREATMENT OF METASTATIC BREAST CANCER
  [ Pharmaceuticals | 2011-02-10]
• EISAI RECEIVES COMPLETE RESPONSE LETTER FROM U.S. FDA FOR INVESTIGATIONAL PROTON PUMP INHIBITOR ACIPHEX® EXTENDED-RELEASE CAPSULES, 50 MG
  [ Pharmaceuticals | 2011-02-02]
• U.S. SUBSIDIARY H3 BIOMEDICINE INC. UNDERTAKES THE DEVELOPMENT OF NEXT-GENERATION CANCER DRUGS
  [ Pharmaceuticals | 2011-01-28]
• PHASE III STUDY FOR SEVERE SEPSIS TREATMENT ERITORAN (E5564) DOES NOT MEET PRIMARY ENDPOINT
  [ Pharmaceuticals | 2011-01-25]
• EISAI TO SUBMIT MARKETING AUTHORIZATION APPLICATIONS IN THE U.S. AND EU FOR PERAMPANEL AS ADJUNCTIVE THERAPY FOR REFRACTORY PARTIAL SEIZURES IN PATIENTS WITH EPILEPSY
  [ Pharmaceuticals | 2011-01-25]
• NOTICE REGARDING CORPORATE NAME CHANGE OF SUBSIDIARY SANKO JUNYAKU CO., LTD.
  [ Pharmaceuticals | 2011-01-25]
• HALAVEN™ RECEIVES CHMP POSITIVE OPINION FOR USE IN METASTATIC BREAST CANCER
  [ Pharmaceuticals | 2011-01-24]
• EISAI RECEIVES APPROVAL TO MARKET BOTULINUM TOXIN TYPE B NEUROMUSCULAR-BLOCKING AGENT NERBLOC® INTRAMUSCULAR INJECTION 2500 UNITS IN JAPAN
  [ Pharmaceuticals | 2011-01-21]
• EISAI RECIEVES APPROVAL TO MARKET BOTULINUM TOXIN TYPE B NEUROMUSCULAR-BLOCKING AGENT NERBLOC® INTRAMUSCULAR INJECTION 2500 UNITS IN JAPAN
  [ Pharmaceuticals | 2011-01-21]
• FINAL NICE APPRAISAL RECOMMENDS IMPROVED ACCESS TO TREATMENT AND CARE OF PEOPLE WITH EARLY ALZHEIMER’S DISEASE
  [ Pharmaceuticals | 2011-01-18]
• EISAI SIGNS PUBLIC-PRIVATE PARTNERSHIP AGREEMENT WITH APOLLO HOSPTIALS AND HELPAGE INDIA TO IMPROVE ACCESS TO MEDCINES IN INDIA
  [ Pharmaceuticals | 2011-01-17]

Most Popular: "Eisai Co., Ltd."